Drug Companies Get Fast-Track Status For Alzheimer’s Medicine

LONDON—AstraZeneca PLC said Monday that the Alzheimer’s drug it is codeveloping with Eli Lilly & Co. has received fast-track designation from the U.S. Food and Drug Administration, a status designed to speed up the development of promising new medicines.

Read more on The Wall Street Journal